Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) Director Bruno Lucidi sold 22,619 shares of the firm's stock in a transaction dated Thursday, November 19th. The shares were sold at an average price of $3.94, for a total value of $89,118.86. Following the sale, the director owned 187,990 shares in the company, valued at $740,680.60. This trade represents a 10.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Bruno Lucidi also recently made the following trade(s):
- On Tuesday, November 17th, Bruno Lucidi sold 6,741 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $4.03, for a total value of $27,166.23.
Atea Pharmaceuticals Price Performance
NASDAQ AVIR traded down $0.06 during trading hours on Thursday, reaching $3.93. The company's stock had a trading volume of 291,342 shares, compared to its average volume of 301,285. The firm has a market capitalization of $315.58 million, a price-to-earnings ratio of -2.02 and a beta of 0.76. Atea Pharmaceuticals, Inc. has a 1-year low of $2.92 and a 1-year high of $6.45. The company's 50-day moving average is $4.68 and its two-hundred day moving average is $4.94.
Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.51) by $0.11. Equities analysts forecast that Atea Pharmaceuticals, Inc. will post -1.60 EPS for the current fiscal year.
Top Atea Pharmaceuticals Stories
Here are a few of the latest stories about AVIR:
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc purchased a new stake in Atea Pharmaceuticals during the 2nd quarter worth approximately $33,000. Quantinno Capital Management LP purchased a new position in shares of Atea Pharmaceuticals in the first quarter valued at approximately $86,000. Spark Investment Management LLC purchased a new position in shares of Atea Pharmaceuticals in the second quarter valued at approximately $75,000. Headlands Technologies LLC acquired a new stake in shares of Atea Pharmaceuticals in the second quarter worth approximately $77,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of Atea Pharmaceuticals in the second quarter worth approximately $78,000. 86.67% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on AVIR shares. Wall Street Zen upgraded Atea Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, September 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Atea Pharmaceuticals in a report on Thursday, October 15th. Finally, Morgan Stanley boosted their price target on shares of Atea Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $8.00.
Get Our Latest Research Report on Atea Pharmaceuticals
Atea Pharmaceuticals Company Profile
(
Get Free Report)
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company's investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Atea Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atea Pharmaceuticals wasn't on the list.
While Atea Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.